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Abstract
Background: Prostate cancer is a common and heterogeneous disease, where androgen receptor (AR) signaling plays a
pivotal role in development and progression. The initial treatment for advanced prostate cancer is suppression of androgen
signaling. Later on, essentially all patients develop an androgen independent stage which does not respond to anti
hormonal treatment. Thus, alternative strategies targeting novel molecular mechanisms are required. b-TrCP is an E3 ligase
that targets various substrates essential for many aspects of tumorigenesis.
Methodology/Principal Findings: Here we show that b-TrCP depletion suppresses prostate cancer and identify a relevant
growth control mechanism. shRNA targeted against b-TrCP reduced prostate cancer cell growth and cooperated with
androgen ablation in vitro and in vivo. We found that b-TrCP inhibition leads to upregulation of the aryl hydrocarbon
receptor (AhR) mediating the therapeutic effect. This phenomenon could be ligand independent, as the AhR ligand 2,3,7,8-
Tetrachlorodibenzo-p-Dioxin (TCDD) did not alter prostate cancer cell growth. We detected high AhR expression and
activation in basal cells and atrophic epithelial cells of human cancer bearing prostates. AhR expression and activation is
also significantly higher in tumor cells compared to benign glandular epithelium.
Conclusions/Significance: Together these observations suggest that AhR activation may be a cancer counteracting
mechanism in the prostate. We maintain that combining b-TrCP inhibition with androgen ablation could benefit advanced
prostate cancer patients.
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Introduction
Prostate cancer is the sixth most common cancer in the world
and the third leading cause of cancer in men. In developed
countries, prostate cancer develops in one of every nine men older
than 65 years. This is a heterogeneous disease in terms of its
clinical course and outcome but androgen signaling seems to be a
common feature in its development and progression [1]. AR
signaling is known to regulate normal, benign and cancerous
prostate cells in various processes (e.g. differentiation and
proliferation). In addition, there are observations indicating that
AR expression is oncogenic in prostate epithelium and promotes
progression to androgen independence [2–8]. The initial treat-
ment of advanced stage and metastatic prostate cancer is
suppression of androgen production by specific drugs or surgical
castration. Later on, essentially all patients develop an androgen
independent stage which does not respond to anti hormonal
treatment. The latter phase is always lethal; thus, alternative
strategies targeting novel molecular mechanisms are required.
The ubiquitin–proteasome system is a crucial determinant of
virtually all biological processes in eukaryotes. In this pathway,
proteins are targeted for degradation by covalent ligation to
ubiquitin, a highly conserved small protein. Protein ubiquitination
involves the concerted action of the E1 ubiquitin-activating
enzyme, an E2 ubiquitin-conjugating enzyme and an E3
ubiquitin-protein ligase, the last of which delivers multiple
ubiquitin molecules to the target protein [9–11]. Inhibiting the
entire ubiquitin proteasome pathway has therapeutic value in
cancer (e.g. Bortezomib,[12]). However, since proteasome inhib-
itors have pleiotropic effects, inhibition of a single key E3 may
offer a more specific treatment option with fewer side effects.
Beta-transducin repeats-containing proteins (b-TrCP) serve as
the substrate recognition subunits for the SCF
b-TrCP E3 ubiquitin
ligases. These ligases ubiquitinate phosphorylated substrates
specifically and play a pivotal role in the regulation of cell division
and various signal transduction pathways, which in turn, are
essential for many aspects of tumorigenesis [13]. There are two b-
TrCP genes in mammalian genomes encoding for the two highly
redundant proteins b-TrCP1 and b-TrCP2. In recent years,
diverse b-TrCP substrates involved in different normal and
malignant pathways were discovered [14–23]. Two well charac-
terized bona fide substrates are b-catenin and IkB. Degradation of
the latter frees NF-kB to enter the nucleus and induce
transcription [11,24–27]. On the other hand, b-catenin is
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the proteasome[24]. Thus, b-TrCP has opposing effects on two
key oncogenic pathways. While the role of b-catenin in prostate
cancer is controversial [28,29], there is evidence suggesting that
NF-kB plays a pro-tumorigenic role in prostate cancer [30–32].
The opposed effect on these two oncogenic proteins exemplifies
the versatility of this particular E3 ligase. Furthermore, b-TrCP is
directly implicated in several cancer types [33–36], thus it is
plausible to further inquire its role in prostate cancer.
In this work, we show that b-TrCP inhibition inhibits prostate
cancer growth showing additive effect with androgen ablation, in
vitro and in vivo. This effect is largely mediated via activation of the
aryl hydrocarbon receptor (AhR) as knocking down this protein
abolishes the effect of b-TrCP inhibition.
Results
NF-kB Activation Correlates with Prostate Cancer
Patients’ Outcome
b-TrCP is an important E3 ligase known to regulate many
different substrates. NF-kB is a well characterized transcription
factor negatively regulated by IkB, thus indirectly positively
modulated by b-TrCP. The involvement of NF-kB in prostate
cancer is well investigated and previous studies showed its
tumorogenic role in the prostate. There is also recent indication
for NF-kB involvement in the progression of prostate cancer to
androgen independent stage [37]. In order to corroborate the
relevance of this factor to prostate cancer progression, we tested its
activation state in primary human prostate cancer samples using
immunohistochemical staining with antibodies against p65
(Figure 1A). 131 prostate cancer specimens, spotted on a single
tissue microarray slide from patients with different Gleason grades
were analyzed. 39% of the samples showed at least some p65
positive nuclei (Figure 1B). We also analyzed 14 prostate cancer
metastases, 64% of which were positive (Figure 1A, B). We set to
evaluate the correlation between prostate cancer Gleason score
and NF-kB activation. Indeed, we found an association between
the two (p=0.014, Fisher’s exact test). It appeared that NF-kB
nuclear staining was stronger in patients with higher Gleason score
or in metastases raising the possibility that NF-kB activation could
be correlated with prognosis. To test this possibility, we
immunstained 80 primary tumors for p65, from patients that
underwent radical prostatectomy and for which we had clinical
follow-up. 77% of the patients whose primary tumor samples
negatively stained for nuclear p65, showed no recurrence up to 8
years post radical prostatectomy. In contrast, the disease recurred
in 65% of the NF-kB positive patients (Figure 1C). Another
important pro-oncogenic b-TrCP substrate is b-catenin. Since b-
TrCP inhibition would enhance b-catenin stability and promote
tumorigenesis, it was necessary to monitor also b-catening
correlation to prostate cancer patients’ outcome. Nuclear
localization of b-catenin activation did not correlate with disease
severity in the same cohort of patients (Figure S1). Together, these
results imply a clinical advantage for inhibiting b-TrCP in prostate
cancer. Yet, the multitude of b-TrCP substrates (37, with possibly
more to be identified) precludes a comprehensive analysis of all of
Figure 1. NF-kB activation correlates with prostate cancer patients’ outcome. Prostate cancer sections were immunostained using p65
antibodies. A. Representative photomicrographs of a primary tumor (left) and lymph node metastasis (right) from the same patient. B. Percent of
negative, positive and strongly positive cases spotted on a tissue microarray from the indicated Gleason scores (p=0.0014, Fisher’s exact test). C.
primary prostate tumors (n=131) were immunostained for p65 and assessed for NF-kB activity. Kaplan-Meier plot revealed a correlation between NF-
kB status and the risk for disease recurrence. Blue, strongly stained samples; Red, weakly stained samples; Green, negative stained samples (p=0.02).
doi:10.1371/journal.pone.0009060.g001
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the utility of b-TrCP inhibition in prostate cancer.
b-TrCP Inhibition Reduces Prostate Cancer Cell Growth
We next examined the effect of b-TrCP inhibition on prostate
cancer cell growth. To this end, we constructed a doxycycline
inducible shRNA lentiviral vector targeting both b-TrCP1 and b-
TrCP2 with which we transduced the two androgen-sensitive
human prostate cancer cell lines, LNCaP and LAPC4. Doxycy-
cline treatment of the trasnduced LNCaP cells resulted in efficient
knock down of both b-TrCP genes (85% and 75% for b-TrCP1
and b-TrCP2, respectively) as determined using quantitative real
time PCR (qRT PCR - Figure 2A). This was accompanied by
IkBa stabilization both before and following TNF stimulation,
demonstrating efficient induction of protein down regulation
(Figure 2B). To evaluate the consequence of b-TrCP knock down
on prostate cancer cells, we monitored doxycycline-treated and
untreated LNCaP cells for nine days and measured cell growth in
vitro. Figure 2C shows diminished cell growth after either b-TrCP
inhibition or androgen ablation treatment (lower left and upper
right panels, respectively). Moreover, combining b-TrCP inhibi-
tion with androgen ablation shows an additive effect (Figure 2C
lower right panel and Figure 2D). We next quantified cell growth
using the XTT method and confirmed our morphologic analysis
(Figure 2D). Similar results were obtained with LAPC4 cells
(Figure S2).
To rule out shRNA off target effects, we used a previously
described b-TrCP dominant negative construct lacking the F-box
domain [33]. This variant stabilizes b-TrCP substrates as it binds
the phosphorylated targets, but fails to recruit the additional
components of the SCF complex which are critical for E3 ligase
catalytic activity. The b-TrCP inhibition effects using the
dominant negative form, were essentially similar to the shRNA
results (Figure S3A and B).
b-TrCP Inhibition Cooperates with Androgen Ablation In
Vivo
To further analyze the effect of b-TrCP inhibition on human
prostate cancer tumor growth, we used a xenograft model. We
injected LNCaP cells carrying an inducible b-TrCP shRNA
construct into the subcutis of 39 immunosuppressed Balb/c
Rag1
2/2 male mice. 25 of the mice (64%) developed visible and
measurable tumors 30 days post injection. Since initial tumor
development was somewhat heterogeneous in size and kinetics,
we randomly divided these 25 mice into four treatment groups:
1. Intact untreated mice (NT, n=4; mean tumor volume
123.1670.7); 2. Mice given tetracycline in the drinking water
resulting in b- T r C Pi n h i b i t i o n( T e t ,n=5 ;m e a nt u m o rv o l u m e
80.3698.2); 3. Castrated mice resulting in androgen ablation
(Cast, n=7; mean tumor volume 121.6695.0); 4. Castration
plus tetracycline (Cast + Tet, n=8; mean tumor volume
180.36143.9). There was no significant difference in average
tumor size at initiation of treatment between the four groups.
We monitored tumor growth once a week, and sacrificed the
mice 30 days post the initial treatment. RNA extracted from
tumors from the Tet treated mice showed b-TrCP knock down
Figure 2. b-TrCP inhibition reduces prostate cancer cells growth. LNCaP cells were infected with a lentiviral vector bearing an inducible
doxycycline dependent b-TrCP shRNA. A. Cells were treated for 72 hours with 1 mg/ml doxycycline and RNA levels of b-TrCP1 and b-TrCP2 were
measured using qRT PCR. B. Western blot analysis of protein extracts from cells treated with TNF, doxycycline or MG-132 were immunoblotted with
either IkB or tubulin. C. Representative photomicrograph of cells treated as indicated and stained with hematoxylin and eosin. D. XTT assay used to
quantify cell growth at different time points. DOX, doxycycline; NT, no treatment; FCS, conditioned medium containing fetal calf serum; CSS,
conditioned medium containing androgen depleted serum (charcoal stripped serum). Error bars, SD. * Significantly different from non treated cells
and from each other, p-value,0.01, t-test.
doi:10.1371/journal.pone.0009060.g002
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findings, inhibiting b-TrCP reduced tumor growth with or
without androgen ablation (Figure 3B). Analysis of tumor
proliferation using BrdU immunostaining revealed that the mice
t r e a t e dw i t hb o t ha n d r o g e na b l a t i o na n db-TrCP inhibition
showed the lowest proliferation rates (Figure 3Ca n dF i g u r e
S4). Tumor growth suppression could not be explained via
apoptosis, since anti cleaved caspase-3 immunostaining did not
reveal any differences between treatment groups (Figure 3D).
Similar results were obtained with AT2.1 rat prostate cancer
cells stably transfected with an inducible dominant negative b-
TrCP transgene (Figure S2B). In conclusion, our results indicate
that b-TrCP inhibition suppresses prostate cancer growth both
in vitro and in vivo and shows an additive effect with androgen
ablation.
Aryl Hydrocarbon Receptor (AhR) Is Upregulated upon
b-TrCP Inhibition and Androgen Ablation
To elucidate the molecular pathways that are responsible for the
growth inhibitory effect of b-TrCP depletion in combination with
androgen ablation we conducted a wide range microarray
analysis. LAPC4 cells infected with the shb-TrCP lentiviral vector,
were either left untreated or treated for 72 hours with doxycycline,
charcoal stripped serum or both. cDNA samples were subjected to
microarray analysis using U133 Affimetrix chips probing ,30,000
probe sets. We then sought to identify genes which are
cooperatively affected by both androgen ablation and b-TrCP
inhibition. Among the upregulated genes, were potential anti
inflammatory genes (e.g. ANXA1) and among the prominently
downregulated were prostate specific genes (e.g. KLK2). Yet, the
most dramatic increase was the expression of the aryl hydrocarbon
(dioxin) receptor (AhR). This gene was upregulated upon either
androgen ablation or b-TrCP inhibition and was the most highly
changed gene due to the combined treatment (Figure 4). We
could attribute AhR level upregulation to b-TrCP depletion, since
doxycycline alone did not alter the receptor’s mRNA (Figure S5).
The AhR is a ligand activated transcription factor involved in
organogenesis, in detoxification of endo- and xenobiotics and in
mediating diverse organ-specific toxic responses of dioxins. This
receptor belongs to the basic helix- loop-helix (bHLH)/PAS
(Period -Aryl hydrocarbon receptor nuclear translocator-Single
minded) family of heterodimeric transcriptional regulators.
bHLH/PAS proteins are involved in the control of diverse
physiological processes such as circadian rhythms, organ develop-
ment, neurogenesis, metabolism and the stress response to hypoxia
[38–40]. Recent studies revealed a connection between the AhR
pathway and prostate cancer both in vitro and in vivo, showing that
the AhR interacts and inhibits the AR. Moreover, the AhR acts as
an E3 ligase of the AR [41] and AhR null TRAMP mice show
increased prostate tumorigenesis [42]. We used qRT PCR to
validate the cDNA array analysis. We found that while each
treatment alone increased AhR RNA levels more than 2 folds, the
combined treatment resulted in more than 4 fold upregulation in
both LAPC4 (Figure 4B) and LNCaP cells (Figure S6). To test the
functional activity of the AhR pathway we measured the mRNA
levels of its canonical target cytochrome p450 1A1 (CYP1A1). Our
Figure 3. b-TrCP inhibition cooperates with androgen ablation treatment in vivo. LNCaP cells bearing a tetracycline induced b-TrCP shRNA
construct were injected subcutaneously to immunosuppressed Rag1
2/2 mice. Mice (n$4 in each group) were either untreated (NT), treated with
tetracycline in their drinking water (Tet), physically castrated (Cast) or both (Cast+Tet) for 30 days. Tumor volumes were measured weekly. (A). qRT
PCR for both b-TrCP isoforms was performed on RNA extracted from the tumors harvested at day 30. (B) Tumor growth kinetics. Tissue sections were
stained for BrdU (C) or activated caspase 3 (D) and the proliferation and apoptosis scores, respectively, were determined for each tumor. Shown are
mean 6 standard deviation (A) or 6S.E.M (B, C and D).* p-value,0.05, ** p-value=0.0002, t-test; p-value in C refers to t-test.
doi:10.1371/journal.pone.0009060.g003
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with AhR levels in the 4 treatment groups (Figure 4B). It should be
noted that this upregulation occurred without addition of an
exogenous AhR ligand. Addition of the potent AhR ligand TCDD
further augmented CYP1A1 upregulation (Figure 5C and data
not shown).
Figure 4. Aryl hydrocarbon receptor (AhR) expression is increased after androgen ablation and b-TrCP treatments. A. LAPC4 cells
infected with inducible b-TrCP shRNA were treated for 72 hours with the indicated treatment, subjected to RNA extraction and cDNA microarray
analysis (Affymetrix). After data normalization, gene expression profiles were compared between treatment and the untreated control samples. A.
Heat map dendrogram showing the ten most highly up (red) and down (green) regulated genes due to the combined treatment. Fold change refers
to the combined treatment probes values relative to control. Expression of b-TrCP isoforms is presented below. B. LAPC4 cells infected with the same
lentiviral vector and treated as indicated were subjected to RNA extraction and qRT PCR analysis with the listed primers. CSS, charcoal stripped serum;
DOX, doxycycline; Error bars, SD.
doi:10.1371/journal.pone.0009060.g004
Figure 5. AhR mediates the b-TrCP inhibition phenotype. LNCaP cells infected with an inducible lentiviral vector for shAhR alone (A) or
together with shb-TrCP (B) were treated for 72 hours with the indicated treatments and cell growth was measured by the XTT assay. C. qRT PCR
confirmed b-TrCP and AhR efficient knock down. D. Western blots showing b-catenin stabilization after b-TrCP inhibition and confirming AhR protein
level elevation or knock down due to relevant shRNAs. DOX, doxycycline; FCS, fetal calf serum; CSS, charcoal stripped serum. Error bars, SD.
doi:10.1371/journal.pone.0009060.g005
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Mediated via Upregulation of the Aryl Hydrocarbon
Receptor
To investigate the significance of the AhR pathway activation
following b-TrCP depletion, we first infected LNCaP cells with
inducible AhR shRNA. While doxycycline treatment resulted in
reduced AhR mRNA levels we could not detect any effect on cell
growth (Figure 5A). Next we co-infected LNCaP cells bearing
inducible b-TrCP shRNA with the inducible AhR shRNA vector.
Addition of doxycycline to the medium of double knockdown cells
resulted in reduced b-TrCP mRNA levels, similar to the single
knockdown cells; yet as expected, in these cells AhR levels were
decreased rather than increased both at the mRNA and protein
levels (Figure 5C, D). Thus, the double knockdown cells allow us
to test whether the growth inhibitory effect of b-TrCP modulation
is mediated via AhR upregulation. Indeed, in the double
knockdown LNCaP cells, b-TrCP depletion failed to reduce cell
growth either with or without androgen ablation (Figure 5B).
Similar results were obtained with a different shRNA targeted
against the AhR (data not shown). Interestingly, addition of the
potent exogenous ligand TCDD did not reduce cell growth alone;
nor had it an effect with any of the different treatments (Figure S7).
This suggests that this AhR effect is ligand independent. Western
blot analysis confirmed b-catenin stabilization and the AhR
mRNA upregulation upon b-TrCP inhibition (Figure 5C). Thus,
the double knockdown results indicate that most of the effect of b-
TrCP knockdown is mediated by upregulation of the AhR.
AhR Expression in Prostate Cancer Patients
Observing AhR upregulation upon b-TrCP inhibition in
prostate cancer cells prompted us to inspect AhR status in various
stages of prostate cancer. To address this aim, we collected 39
specimens of primary prostate cancer tumors from the Hadassah
Medical Center. Out of this cohort, 17 patients suffered from
disease recurrence. We performed immunohitochemical anti AhR
staining and monitored cytoplasmatic and nuclear AhR expres-
sion. First, we detected high AhR in basal cells located in the
benign gland perimeter (Figure 6A). Interestingly, proliferative
inflammatory atrophy (PIA), considered as a precursor lesion to
prostate cancer showed very strong cytoplasmic and nuclear
staining (Figure 6B). We used a subjective score from 0 to 3 to
quantitate staining intensity in normal and malignant epithelial
cells in each specimen. Our analysis demonstrates upregulation of
AhR in both the cytoplasmic and nuclear locations in the
malignant epithelium (Figure 6C, D, p,0.001, Mann-Whitney
test). However, we did not observe a correlation between AhR
expression in the tumor cells and disease recurrence (data not
shown).
Discussion
Prostate cancer is a heterogeneous disease comprising many
genetic and phenotypic features. One important hallmark of
prostate cancer is progression to an androgen independent stage
(AI) after hormonal treatment. The causes for this transition are
not fully understood and adjuvant treatments fortifying hormonal
manipulation are required. One factor that is often implicated in
tumor progression in many types of cancer is NF-kB. Here we
confirm that NF-kB is often activated in advanced prostate cancer
patients (Figure 1). Moreover, NF-kB activation correlates with
prostate cancer recurrence (Figure 1C). One of the major
regulators of NF-kB is the E3 ubiquitin ligase SCF
b-TrCP, which
targets IkB as well as many other substrates for ubiquitination and
Figure 6. AhR is upregulated in malignant prostate cells. Prostate sections were immunostained with AhR antibody. Photomicrographs show
strong AhR expression in basal cells (arrows in A) and proliferative inflammatory atrophy (B). C. Higher AhR expression is noted in malignant
glands (T) compared with normal glands (N). D. Normal and malignant glands were scored using a 0–3 scale. Mean values 6S.E.M. are shown
(p-value,0.001, Mann-Whitney test).
doi:10.1371/journal.pone.0009060.g006
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role in certain types of cancers [43]. Based on observed
upregulation of NF-kB, it was important to follow another
common pro-oncogenic b-TrCP substrate, b-catenin, which was
also implicated in prostate cancer [28,29,44]. However, we could
not detect a correlation between b-catenin activation and prostate
cancer recurrence (Figure S1), suggesting that only some b-TrCP
targets are of relevance to the disease progression. To evaluate the
full scope of b-TrCP effects, we set out to inhibit b-TrCP in
prostate cancer cells and to monitor its effect on prostate cancer
cell growth. Our in vitro and in vivo studies revealed that upon b-
TrCP inhibition prostate cancer cell growth is reduced. We could
also detect an additive effect when combining b-TrCP inhibition
with androgen ablation (Figure 2 and 3). To elucidate the
mechanisms of growth suppression by b-TrCP inhibition, we
carried a cDNA array analysis and observed an additive
upregulation of the AhR (Figure 4). AhR was previously
demonstrated to act as an E3 ligase of the AR [41], providing
us a possible link to AR signaling. Moreover, we noted that AhR
expression is higher upon combining androgen ablation and b-
TrCP inhibition. We therefore hypothesized that the upregulation
of the AhR could be mediating the growth inhibitory effect of b-
TrCP knockdown in prostate cancer cells. This notion was
supported by previous reports demonstrating an inhibitory role for
the AhR pathway in prostate cancer. Morrow et al showed an AhR
ligand dependent growth inhibition in LNCaP cells. Likewise,
other studies have also implicated the androgen receptor in AhR
growth inhibition [45,46]. In our study, knocking down the AhR
per se in LNCaP cells did not alter prostate cancer cell growth
(Figure 5A), suggesting that the basal levels of AhR do not exert
an inhibitory effect unless stimulated by ligand. On the other hand
boosting AhR expression via b-TrCP depletion was associated
with considerable ligand-independent growth suppression. AhR
depletion reversed the growth suppression effect of b-TrCP
knockdown, even under androgen ablation, proving that AhR
upregulation, which we also noted in other stress conditions (e.g.
atrophy, inflammation and androgen ablation) accounts for the b-
TrCP inhibitory effect (Figure 5). Interestingly, ligand adminis-
tration did not affect cell growth even though it did upregulate
expression of the classic AhR pathway target CYP1A1. These
results implicate a ligand and CYP1A1 independent AhR pathway
in prostate cancer cells.
Chesire et al identified the AhR as a putative b-catenin target in
LNCaP cells [47]. As we show that b-TrCP depletion stabilizes b-
catenin along with the upregulation of AhR (Figure 5D), it is
possible that the cause of AhR elevation following b-TrCP
depletion is b-catenin stabilization.
Our studies indicate a novel ligand independent strategy of
boosting AhR expression as means of suppressing prostate cancer
growth. This strategy may also be echoed in the natural history of
prostate cancer. We found that AhR is normally expressed at low
levels in the prostatic epithelium basal cells (cytoplasmic and
nuclear staining, Figure 6A) and is substantially upregulated in
areas of proliferative inflammatory atrophy (PIA), considered a
precursor lesion to cancer (Figure 6B). AhR activation in basal
and atrophic cells may therefore be viewed as an anticancer
mechanism. It is possible that microenvironmental inflammatory
signals are responsible for such stress induced signaling. A
mutation in one allele of b-TrCP1 was identified in one human
prostate tumor in a systematic screen of Wnt pathway mutations
[48]. However this mutation is unlikely to have an effect on the
NF-kB pathway as the other allele and possibly both b-TrCP2
alleles were wild type. Similarly, to our knowledge, activating
mutations in the NF-kB pathway were so far not reported in
human prostate tumors. Nevertheless, NF-kB known to mediate
malignant transformation is constitutively upregulated in this
tumor type via multiple mechanisms. We conclude that different
stress signals, including inflammation, atrophy and androgen
ablation upregulate AhR expression in both normal and malignant
prostate cells and conduct a protective mechanism. Inhibiting b-
TrCP at advanced disease stages may be relevant in developing
strategies for enhancing the efficacy of prostate cancer treatments.
Materials and Methods
Ethics Statement
Experiments with human tissues were approved by Institutional
Review Board, Hadassah-Hebrew University Medical Center.
Due to the retrospective nature of this study and according to the
declaration of Helsinki, participants were not obtained constantly
informed. In addition, our IRB waived the need for written
informed consent. All mice experiments were approved by the
IACUC.
Dominant Negative b-TrCP (WD)
Dominant negative b-TrCP (WD) was cloned using E3RS excluded
from pCDNA3-EE-hE3RS plasmids with the primers 59 to 39
forward: GCGGCCGCTATGGACCC-GGCCGAG (with NotI
site in its 59); reverse: TTATCTGGAGATGTAGGTGT; the
product was cloned into TA vector (Invitrogen). The last vector
was cut with AvrII/ASP718, filled in and blunt ligated. The
relevant fragment was cut and inserted into pFLAG-CMV
TM-2
expression vector (Sigma-Aldrich) with NotI/BamHI. This proce-
dure produced a WD construct lacking part of the F-box and
conjugated to FLAG. The WD-FLAG was inserted under
bidirectional teracycline promoter expressing GFP. The resulting
plasmid was transfected into AT2.1 Rat prostate cancer cells
expressing the tetracycline trans-activator, using FUGENE
reagent (Roche Applied Science). The transfected cells were
selected using hygromycin and neomycin (Sigma-Aldrich) con-
taining media to produce a stable clone which expresses a
dominant negative b-TrCP upon addition of tetracycline or its
derivate doxycycline.
Inducible b-TrCP and AhR shRNA
The human shRNA 59- GUGGAAUUUGUGGAACAUC 39
targeted against b-TrCP1 and b-TrCP2 was constructed into
pTER plasmid and inserted into a modified pRRL.sin.PPT.
tetO7.MCS.PRE lentiviral vector. The vector consists of an HI
promoter, tet operator, the shRNA coding sequence and eF1a
promoter driving the tet repressor fused to eGFP. Virus
production and infection were carried out as previously described
[49]. To target the AhR we used the following shRNA sequences:
1. 59 CAGCUGAAUUAAAUAACAU 39;2 .5 9 CAGACAGUA-
GUCUGUUAUA 39. Both of which proved to be efficient in
knocking down the receptor (the presented data represent those
obtain with the latter sequence). shRNA expression is induced only
after Tetracycline or Doxycycline (Sigma-Aldrich) administration.
The vector alone was used as control. Double knocked down
LNCaP cells were designed by co-infecting shb-TrCP cells with
lentiviral vectors carrying either of the above described sequence.
Cell Culture
DMEM, RPMI 1640, Trypsin EDTA, Penicillin-Streptomycin
solution, L-glutamine, fetal calf serum (FCS), Charcoal Stripped
Serum (CSS) were purchased from Biological Industries, Kibbutz
Beit Haemek, Israel. LAPC4 cells were kindly provided by Prof.
Zelig Eschar (The Weizmann Institute of Science, Rehovot,
b-TrCP-AhR in Prostate Cancer
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Rachel Bar-Shavit (Department of Oncology, Hadassah Medical
Center, Jerusalem, Israel). All cell lines were incubated at 37uC
5% CO2 in appropriate medium containing 10% FCS or CSS as
indicated.100 pM Methyltrienolone (R1881, Perkin-Elmer, New
England Nuclear) was added to LAPC4 full media.
Cell Proliferation Assay
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenylte-trazolium
bromide) and XTT (2,3-Bis(2-methoxy-4-nitro-5- sulfophenyl)-
2H-tetrazolium-5-carboxanilide) was used as the protocol indicates
(Biological Industries, Kibbutz Beit Haemek, Israel). All experi-
ments were carried out in 96 well plates with eight repeats of at
least 3 independent infections.
Western Blotting
Whole-cell lysates were prepared from transfected or infected
cells by extraction in lysis buffer containing 50 mM Tris (pH 8),
150 mM NaCl, 1% NP-40, 0.1% SDS, 10 mM NaF, 1 mM
Na3VO4, 1 mM phenylmethylsulfonyl fluoride, 1 mg/ml leupep-
tin, 1 mg/ml aprotinin and 1 mM dithiothreitol. Proteins were
resolved by 10% SDS-PAGE, transferred onto nitrocellulose
membranes, probed with appropriate antibodies, incubated with
Peroxidase-conjugated Goat anti mouse or Rabbit IgG (Jackson
Laboratories) and developed using the ECL kit (Pierce). Primary
antibodies used were: anti-Flag (Sigma); anti-IkB, anti-phpspho-
IkB (Cell Signaling); Aryl Hydrocarbon Receptor, CYP1A1
(Santa-Cruz); phospho-b-catenin (BD Biosciences).
Xenografts
AT2.1 or LNCaP cells were harvested washed and reconstituted
in PBS. 10
6 51B cells per 200 ml volume were injected
subcutaneously to 6–7 weeks old atymic (Nude) male mice. 10
6
LNCaP cells were injected to 6–7 weeks old rag12/2 male mice
together with Matrigel (BD bioscience). Tumors were measured in
two dimensions with caliper, and tumor volume (mm
3) was
calculated with the formula V=(lengthXwidth
2)/2. Half of the
mice received Doxycycline (0.2 mg/ml, AT2.1) or tetracycline
(1.5 mg/ml, LNCaP) supplemented with 5% sucrose in their
drinking water. Half of the mice were surgically castrated: mice
were anesthetized using Ketamine/2% Xylazine at 5.7:1 ratio
(0.1 ml per 25–30 gram mouse). Surgical castration was performed
via a midline scrotal incision allowing bilateral access to the
hemiscrotal contents. After exposing each testicle, a 3-0 Vicryl
suture was used to ligate the spermatic cord and then remove the
testicle. Mice were treated with Carprofen (Rimadyl) as analgesics
after surgery. Two hours before sacrifice, mice were injected with
BrdU intraperitoneally 100 ml per 10 grams of body weight
(RPN201, Amersham Pharmacia Biotech Inc). For AT2.1
xenografts, NUDE mice were treated pre-injection and tumors
were weighted at the end of the experiment. LNCaP xenografted
mice were treated 30 days post injection when measurable tumors
were established. Tumor relative growth was calculated individ-
ually for each mouse, comparing each week’s measurement to the
treatments’ day 0 (30 days post injection). All mice experiments
were approved by the IACUC.
Immunohistochimestry
mouse tumor specimens were fixed in 4% neutral-buffered
formalin and embedded in paraffin. Patients paraffin embedded
samples were collected from the archives of the Department of
Pathology at the Hadassah-Hebrew University Medical Center.
Experiments with human tissues were approved by the institu-
tional review board. 5 mM sections were dewaxed and hydrated
through graded ethanol dilutions, then cooked in appropriate
buffer (pH 7.4) in a pressure cooker at 115uC for 3 minutes.
Endogenous peroxidase activity was blocked with 3% hydrogen
peroxide followed by washing. The sections were then incubated
with the indicated antibodies: anti-p65 (Neomarkers; 1:100), anti-
b-catenin (Santa Cruz; 1:300) and anti-AhR (Santa Cruz; 1:200).
All sections were counterstained with hematoxylin.
RNA, cDNA Micrroarray and Real-Time PCR
Total RNA was extracted from LAPC4 or LNCaP cells infected
with b-TrCP shRNA lentiviral vector with TRI Reagent (Sigma).
For cDNA microarray RNA was extracted from LAPC4 infected
cells using TRIzolH (Invitrogen). cRNA preparation and hybrid-
ization was performed using standard manufacture protocol;
Biotin-labeled target synthesis reactions were performed using
standard protocols supplied by the manufacturer (Affymetrix,
Santa Clara CA, USA). From each RNA sample, 5 mg were
converted into double-stranded cDNA by reverse transcription
with SuperScript
TM II Reverse Transcriptase (Life Technologies,
Helgerman CT, USA), using T7-oligo-dT as a primer. Expression
value (signal) was calculated using Affymetrix Genechip software
MicroArray Suite 5.0. Only probe sets that had at least an
intensity of 20 and a present call at one of the microarrays were
selected. Next quantile normalization was applied to the log2
transformed expression values (Bolstad BM Bioinformatics 19:
185–193). For b-TrCP knockdown determination and validation
studies 2 mg of RNA were used as template for synthesis of cDNA
using SuperScript
TM II Reverse Transcriptase. The cDNA was
subsequently used as Real Time PCR template. All Real Time
PCR reactions were carried out using Absolute Blue QPCR SYBR
Green Low ROX Mix (ABgene) with the following primers (59 to
39): b-TrCP1 Forward: ATCGGATTCCACGGTCAGAG, Re-
verse: AATCAACGTGTTTAGCATT-TCACCT; b-TrCP2 For-
ward: CCATCAAAGTCTGGAGCACGA, Reverse: CGCT-
TGTGCCCATTGAGAGTA; AhR Forward: ACATCACC-
TACGCCAGTCG, Reverse: CTCTATGCCGCTTGGAAG-
GAT; CYP1A1 forward: TGAATGCCTTCAAGGAC-CTG,
Reverse: TCAGGCTGTCTGTGATGTCC.
All microarray data is MIAME compliant. The raw data has
been deposited in GEO (accession number GSE19141).
Supporting Information
Figure S1 b-catenin activation does not correlate with prostate
cancer patients’ outcome. Primary prostate cancer tumors were
immunostained using b-catenin antibodies. A. Representative
photomicrographs of samples from negative (left) and positive
(right) b-catenin stained tumors. B. Kaplan Meier curves plotting
b-catenin positive (blue) vs. negative (green) patients’ recurrence
free interval. Scale bars in A, 50 mM.
Found at: doi:10.1371/journal.pone.0009060.s001 (1.02 MB TIF)
Figure S2 b-TrCP shRNA cooperates with androgen ablation to
reduceLAPC4cellgrowth.LAPC4cell infected with thementioned
inducible lentiviral vector containing b-TrCP shRNA. A. qRT-
PCR demonstrating efficient b-TrCP1 and b-TrCP2 knockdown.
B.XTT assaywasused toquantify cellsproliferationrates (means6
S.E.M.). Error bars in A, SD. NT, no treatment; DOX,
doxycycline; CSS, charcoal stripped serum. * All treatments were
statistically different from control (p-value,0.05, t-test).
Found at: doi:10.1371/journal.pone.0009060.s002 (0.19 MB TIF)
Figure S3 Dominant negative b-TrCP expression inhibits
prostate cancer cell growth in vitro and in vivo. A. AT2.1 cells
b-TrCP-AhR in Prostate Cancer
PLoS ONE | www.plosone.org 8 February 2010 | Volume 5 | Issue 2 | e9060stably transfected with an inducible dominant negative b-TrCP
were treated as indicated for 72 hours and subjected to MTT cell
proliferation assay. B. LNCaP cells infected with lentiviral vector
expressing eGFP (GFP) or dominant negative b-TrCP (DF-box)
and assayed using the XTT reagent. C. Athymic 6–8 weeks male
NUDE mice were divided into the 4 indicated groups (n$4) and
subcutaneously grafted with AT2.1 cells bearing the doxycycline
dependent dominant negative b-TrCP construct. Tumor volumes
were measured two weeks post injection. Shown are means 6
S.E.M for A and C and means 6 SD for B. * Significantly
different from control group (p,0.05, t-test); ** Significantly
different from all treatment groups (p,0.01, t-test). NT, no
treatment; DOX, doxycycline; CSS, charcoal stripped serum;
Cast, castrated mice.
Found at: doi:10.1371/journal.pone.0009060.s003 (0.20 MB TIF)
Figure S4 b-TrCP inhibition cooperates with androgen ablation
treatment to reduce prostate cancer cells proliferation in vivo.
LNCaP xenografts from treated Rag1
2/2 mice were immuno-
stained with anti BrdU antibodies. Representative photomicro-
graphs for each of the four treatment groups are shown. NT, no
treatment; cast, castrated mice; Tet, tetracycline.
Found at: doi:10.1371/journal.pone.0009060.s004 (2.87 MB TIF)
Figure S5 Doxycycline does not upregulate AhR. LNCaP cells
infected with a GFP expressing lentiviral vector were subjected to
qRT PCR analysis with the indicated primers. Means 6 S.E.M of
the relative genes expressions are shown. NT, no treatment; DOX,
doxycycline.
Found at: doi:10.1371/journal.pone.0009060.s005 (0.12 MB TIF)
Figure S6 b-TrCP inhibition upregulates the AhR in LNCaP
cells. LNCaP cells infected with an inducible shb-TrCP lentiviral
vector and treated as indicated were subjected to RNA extraction
and qRT PCR analysis with the listed primers. CSS, charcoal
stripped serum; DOX, doxycycline; Error bars, SD.
Found at: doi:10.1371/journal.pone.0009060.s006 (0.33 MB TIF)
Figure S7 TCDD does not alter LNCaP cell growth in vitro.
LNCaP cells were infected with a lentiviral vector harboring an
inducible doxycycline dependent b-TrCP shRNA. Cells were
treated with 1 mg/ml doxycycline, 10 nM TCDD or both and
XTT assay was used to quantify cell growth at different time
points. Shown are means 6 SEM. NT, no treatment; DOX,
doxycycline.
Found at: doi:10.1371/journal.pone.0009060.s007 (0.07 MB TIF)
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